COMMUNIQUÉS West-GlobeNewswire

Certara to Participate in Upcoming Investor Conferences
18/05/2026
RADNOR, Pa., May 18, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor [...]
Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
18/05/2026
– Oral presentation highlights efficacy and safety profile of lorundrostat in patients with uncontrolled hypertension and chronic kidney disease – RADNOR, Pa., May 18, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, [...]
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
18/05/2026
BRISBANE, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that [...]
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18/05/2026
FOSTER CITY, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective May 15, 2026, it granted stock options to purchase an [...]
Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update
18/05/2026
- Groundbreaking interim results from U.S. REGAIN trial in recurrent glioblastoma demonstrate 100% local disease control, 67% complete response rate, and favorable safety profile - - Completion of patient enrollment in [...]
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
18/05/2026
WATERTOWN, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that [...]
Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland
18/05/2026
Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease, having met the primary endpoint, reductions in lesion growth rate, in the pivotal, global Phase 3 DRAGON trial [...]
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
18/05/2026
SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 15, 2026 it granted stock options to purchase an aggregate of 20,807 shares of common [...]
Memopezil Claims Evaluated (2026 Official Website Scam WARNING Update) Avoid Fake Complaints & Hidden Risks
18/05/2026
Bacopa, Rhodiola, L-Theanine, BCAAs, and Panax Ginseng Reviewed: Memopezil Ingredients, Supplement Facts, and Cognitive Support Formula Explained Largo, FL, May 18, 2026 (GLOBE NEWSWIRE) -- These statements have not [...]
Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD
18/05/2026
ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD Data from the head-to-head study show efdoralprin alfa normalized [...]
Communiqué de presse : ATS : Les données de phase 2 démontrent la supériorité de l'efdoralprin alfa par rapport au traitement de substitution standard pour atteindre des taux de fAAT plus élevés dans le DAAT
18/05/2026
ATS : Les données de phase 2 démontrent la supériorité de l'efdoralprin alfa par rapport au traitement de substitution standard pour atteindre des taux de fAAT plus élevés dans le DAAT Les données de l’étude comparative [...]
Chemed Corporation Holds Annual Meeting of Stockholders; Board Declares Quarterly Dividend
18/05/2026
CINCINNATI, May 18, 2026 (GLOBE NEWSWIRE) -- Stockholders of Chemed Corporation (NYSE: CHE) today elected a slate of nine directors at the Company’s 2026 annual stockholders’ meeting. Stockholders ratified the [...]
Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
18/05/2026
GAITHERSBURG, Md., May 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it granted equity awards on May 13, 2026 [...]
Ipsen - April 2026- Monthly information relative to the total number of voting rights and shares composing the share capital
18/05/2026
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation [...]
NADP: provider, patient benefits rose; dental plan enrollment fell in 2024
18/05/2026
Affordability pressures drive shift toward voluntary plans DALLAS, May 18, 2026 (GLOBE NEWSWIRE) -- Despite a 2024 dip in U.S. dental plan enrollment, dental benefits companies increased payments per member to dental [...]
Ipsen - Avril 2026 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
18/05/2026
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerce et à l’article 223-16 du Règlement Général de l’ [...]
Letter to Shareholders from CEO Dr. Ryan Saadi
18/05/2026
WARREN, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ). Dear Shareholders, Since Tevogen’s 2024 public listing, we have remained focused on building a [...]
Disclosure of transparency notifications from BlackRock, Inc.
18/05/2026
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 18 May 2026 – 6 PM CET Disclosure of transparency notifications from BlackRock, Inc. Pursuant to the Belgian act of 2 May 2007 on the disclosure of [...]
Carbios annonce une évolution de sa gouvernance et la nomination de Benoît Grenot en qualité de Directeur Général.
18/05/2026
Clermont-Ferrand (France), 18 mai 2026 (17h45 CEST). Carbios (Euronext Growth Paris : ALCRB) annonce une évolution de sa gouvernance. Ayant à 64 ans fait part de sa volonté de partir à la retraite, Vincent Kamel [...]

Pages